Company Overview

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$67.25
Change (%) Stock is Up 1.35 (2.05%)
Volume90,197
Data as of 02/21/18 9:50 a.m. ET
Refresh quote
Featured Events
Corporate Presentation
Download Documentation Corporate Presentation (February 2018)
Download Documentation GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting Presentation
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
02/07/18GBT Announces Participation at the Leerink Partners 7th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 9:00 a.m. Eastern Time. The presentation will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About Global Blood Therapeutics GBT is a clinical-stage biopharmaceutical compa... 
Printer Friendly Version
01/09/18GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)
Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation SOUTH SAN FRANCISCO, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously... 
Printer Friendly Version
01/03/18GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. Pacific Time. The presentation and Q&A session will be webcast live and available for replay from GBT’s website at www.gbt.com in the Investors section. About GBT GBT is a clinical-stage biopharmaceutical company determined to discover, deve... 
Printer Friendly Version
12/22/17GBT Appoints Wendy L. Yarno to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the appointment of Wendy L. Yarno to the company’s board of directors. Ms. Yarno has more than 25 years of experience in the biopharmaceutical industry, including serving as chief marketing officer at Merck & Co. Inc. “Wendy is an accomplished biopharmaceutical executive with a proven track record in building and leading organizations, and has significant exp... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.